Health Catalyst (NASDAQ:HCAT) Upgraded by KeyCorp to “Overweight” Rating

KeyCorp upgraded shares of Health Catalyst (NASDAQ:HCAT) from a sector weight rating to an overweight rating in a research note issued to investors on Wednesday morning, Marketbeat reports. KeyCorp currently has $9.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Citigroup lifted their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Evercore ISI increased their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Stephens boosted their target price on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Royal Bank of Canada upped their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Health Catalyst Price Performance

HCAT opened at $7.36 on Wednesday. The stock has a market cap of $447.84 million, a P/E ratio of -5.45 and a beta of 1.36. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a fifty day simple moving average of $7.82 and a 200 day simple moving average of $7.52.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter last year, the company earned ($0.22) earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year. On average, research analysts expect that Health Catalyst will post -0.33 EPS for the current year.

Insider Activity at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the sale, the insider now directly owns 236,950 shares in the company, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the transaction, the insider now owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. The trade was a 6.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 68,342 shares of company stock valued at $554,695. 2.50% of the stock is owned by insiders.

Institutional Trading of Health Catalyst

Several large investors have recently modified their holdings of the business. Franklin Resources Inc. raised its stake in shares of Health Catalyst by 5.8% in the third quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock worth $857,000 after purchasing an additional 5,687 shares during the last quarter. Geode Capital Management LLC lifted its position in Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after purchasing an additional 66,896 shares in the last quarter. Zacks Investment Management raised its stake in Health Catalyst by 6.7% during the 3rd quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock worth $2,410,000 after acquiring an additional 18,677 shares during the period. State Street Corp grew its holdings in Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after buying an additional 28,251 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new position in shares of Health Catalyst during the 3rd quarter valued at about $84,000. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.